Drug patents dont usually fail loudly. They fail quietlyat the seams.
Heres the uncomfortable truth in pharma IP: when device patents enter the picture, they often dont topple a drug fortress overnight. They probe first where the structure is weakestth…

A quiet patent upgrade can wipe out a whole competitorwithout you ever seeing the lawsuit.
In pharma, everyone watches the big battles: new drug approvals, blockbuster exclusivities, landmark court decisions. But theres a less visible pattern that can …

Pediatric exclusivity was supposed to be a shield. In 2025, its starting to look like a fuse.
For years, the argument was elegant: extend market exclusivity if sponsors run pediatric studies, generate real-world evidence for children, and ultimately im…

Bausch + Sun: When Generic Certainty Meets the Reality of Patent Strategy
If youve spent any time in pharma, you know the story always sounds the sameuntil it doesnt.
One company wants certainty that a product can launch. Another wants time. And somewh…

Exelixis vs. Intas: When Big Pharma Meets Real-World Patent Strategyand the Stakes Get Personal
Patent litigation is often framed as courtroom dramaclaims, counters, and countdowns until a decision lands. But the more interesting story is what happens …

Exelixis v. Handa: The Patent Fight That Signals Where Oncology IP Is Headed
On its face, Exelixis Inc. v. Handa Pharmaceuticals Inc. reads like another chapter in the long-running battle between branded innovators and generic challengers. But the bigg…

Takeda v. Sun Pharma: The quiet stakes behind a simple patent fight
If youve spent any time in pharma, you know the surface story is often the least interesting part. A complaint is filed. Claims are asserted. Motions follow. Then everyone waits for a …

Vertex Pharmaceuticals v. Squires: When Patent Strategy Meets the Real World of Patient Access
There are court casesand then there are court cases that quietly reshape timelines, leverage, and ultimately access to medicines.
The dispute between Vertex …